Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Yann Godbert et al.|New England Journal of Medicine|2020Cited by 766
An expanded universe of cancer targetsWilliam C. Hahn, Jitong Cai, Joel S. Bader et al.|Cell|2021Cited by 221
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker AnalysesTaofeek K. Owonikoko, David R. Spigel|Journal of Thoracic Oncology|2019Cited by 146
Systematic discovery of mutation-directed neo-protein-protein interactions in cancerXiulei Mo, Haian Fu, Qiankun Niu et al.|Cell|2022Cited by 75
Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung CancerGuojing Zhang, Taofeek K. Owonikoko|Cancers|2025Cited by 2